Finch Therapeutics develops microbiome-based therapeutics aimed at addressing serious unmet medical needs through insights gained from human microbiota transplantation studies. The company has established a robust intellectual property portfolio that supports a range of therapeutic applications in the microbiome field.
Funding
$90M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Finch Therapeutics focused on developing microbiome-based therapeutics to address unmet medical needs. Their primary approach involved leveraging insights from human microbiota transplantation studies. However, the company discontinued its Phase 3 trial of CP101 in recurrent _C. difficile_.
Solution
Finch Therapeutics has established a portfolio of microbiome assets designed with insights from human microbiota transplantation studies. The company's strategy now centers on realizing the value of its intellectual property estate and other assets. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field.
Target Audience
Entities interested in exploring partnerships or learning more about Finch's portfolio.
Features
- Portfolio of microbiome assets.
- Intellectual property estate.